citalopram has been researched along with Dyskinesia, Drug-Induced in 13 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo." | 5.24 | Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. ( Baer, L; Bobo, WV; Curren, L; Fava, M; Mischoulon, D; Papakostas, GI; Shelton, RC, 2017) |
| "People diagnosed with depression also tend to have a co-morbid nicotine addiction." | 3.78 | Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter. ( Bevins, RA; Dion, AM; Murrin, LC; Sanderson, SC, 2012) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Citalopram was continued and spontaneous improvement was noticed in the following weeks." | 1.43 | Citalopram-induced dyskinesia of the tongue: a video presentation. ( Gaanderse, M; Kliffen, J; Linssen, W, 2016) |
| "The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile." | 1.42 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015) |
| "Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures." | 1.34 | Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. ( Brahm, NC; Brown, RC; McElwain, DL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conti, MM | 2 |
| Ostock, CY | 2 |
| Lindenbach, D | 2 |
| Goldenberg, AA | 2 |
| Kampton, E | 1 |
| Dell'isola, R | 1 |
| Katzman, AC | 1 |
| Bishop, C | 3 |
| Palumbo, N | 1 |
| Vilceus, N | 1 |
| Fidalgo, C | 1 |
| Ko, WK | 1 |
| Tronci, E | 1 |
| Li, Q | 1 |
| Stancampiano, R | 1 |
| Chuan, Q | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Mischoulon, D | 1 |
| Shelton, RC | 1 |
| Baer, L | 1 |
| Bobo, WV | 1 |
| Curren, L | 1 |
| Fava, M | 1 |
| Papakostas, GI | 1 |
| Gaanderse, M | 1 |
| Kliffen, J | 1 |
| Linssen, W | 1 |
| Park, YM | 1 |
| Lee, HJ | 1 |
| Kang, SG | 1 |
| Choo, CS | 1 |
| Cho, JH | 1 |
| Muthusami, S | 1 |
| Basu, S | 1 |
| Kumar, A | 1 |
| Dash, A | 1 |
| Dion, AM | 1 |
| Sanderson, SC | 1 |
| Murrin, LC | 1 |
| Bevins, RA | 1 |
| George, JA | 1 |
| Buchta, W | 1 |
| Mohamed, M | 1 |
| Dickinson, SO | 1 |
| Eissa, S | 1 |
| Eskow Jaunarajs, KL | 1 |
| Brahm, NC | 1 |
| McElwain, DL | 1 |
| Brown, RC | 1 |
| Duggal, HS | 1 |
| Mendhekar, DN | 1 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| Korsgaard, S | 1 |
| Noring, U | 1 |
| Povlsen, UJ | 1 |
| Gerlach, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatmen[NCT00633399] | Phase 2 | 458 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This will involve looking at the change in HAM-D 17 scores during phase 2. For HAMD-17 the minimum is 0, the maximum is 52, and greater scores represent more symptoms. (NCT00633399)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ziprasidone + Escitalopram | -6.4 |
| Placebo + Escitalopram | -3.3 |
A secondary outcome measure will be remission rates (HAM-D 17 scores of less than 8) after treatment phase 2.. A remitted will be a patient with a final score of 7 or less on the HAMD-17 during phase 2. (NCT00633399)
Timeframe: 8 weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Ziprasidone + Escitalopram | 38 |
| Placebo + Escitalopram | 30 |
The primary outcome measure will be response rates (50% decrease in HAM-D-17 scores) during phase 2. A responder will be a patient who experiences a 50% or greater decrease in symptoms according to the HAM-D-17 during phase 2. (NCT00633399)
Timeframe: 8 Weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Ziprasidone + Escitalopram | 35.2 |
| Placebo + Escitalopram | 20.5 |
1 trial available for citalopram and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Citalopram; Depressive Disor | 2017 |
12 other studies available for citalopram and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Acti | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, | 2015 |
Citalopram-induced dyskinesia of the tongue: a video presentation.
Topics: Anxiety Disorders; Citalopram; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Remission, Spont | 2016 |
Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzamides; Benzyl Compounds; B | 2009 |
Acute dyskinesia and extrapyramidal disorder in a child after ingestion of escitalopram.
Topics: Acute Disease; Alprazolam; Anti-Anxiety Agents; Anxiety; Basal Ganglia Diseases; Chest Pain; Child; | 2009 |
Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Discrimination Learning; Dose-Response | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskin | 2012 |
Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Baclofen; Basal Ganglia Diseases; Citalopram; | 2007 |
A case report of reemergence of antipsychotic-induced dyskinesia with citalopram.
Topics: Antipsychotic Agents; Bipolar Disorder; Citalopram; Dyskinesia, Drug-Induced; Humans; Male; Middle A | 2007 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Citalopram; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced | 1986 |